S&P 500   4,352.63 (-2.04%)
DOW   34,299.99 (-1.63%)
QQQ   359.53 (-2.92%)
AAPL   141.83 (-2.44%)
MSFT   283.30 (-3.70%)
FB   340.45 (-3.71%)
GOOGL   2,718.74 (-3.64%)
TSLA   775.75 (-1.97%)
AMZN   3,316.98 (-2.61%)
NVDA   206.13 (-4.83%)
BABA   152.44 (+1.50%)
NIO   35.05 (-4.68%)
CGC   14.23 (-3.26%)
GE   105.72 (+0.35%)
MU   70.57 (-6.13%)
AMD   101.02 (-6.60%)
T   27.23 (-0.62%)
F   14.32 (+1.13%)
ACB   6.81 (+6.57%)
DIS   174.45 (-2.14%)
PFE   43.05 (-1.19%)
BA   218.64 (-2.46%)
AMC   36.82 (-6.31%)
S&P 500   4,352.63 (-2.04%)
DOW   34,299.99 (-1.63%)
QQQ   359.53 (-2.92%)
AAPL   141.83 (-2.44%)
MSFT   283.30 (-3.70%)
FB   340.45 (-3.71%)
GOOGL   2,718.74 (-3.64%)
TSLA   775.75 (-1.97%)
AMZN   3,316.98 (-2.61%)
NVDA   206.13 (-4.83%)
BABA   152.44 (+1.50%)
NIO   35.05 (-4.68%)
CGC   14.23 (-3.26%)
GE   105.72 (+0.35%)
MU   70.57 (-6.13%)
AMD   101.02 (-6.60%)
T   27.23 (-0.62%)
F   14.32 (+1.13%)
ACB   6.81 (+6.57%)
DIS   174.45 (-2.14%)
PFE   43.05 (-1.19%)
BA   218.64 (-2.46%)
AMC   36.82 (-6.31%)
S&P 500   4,352.63 (-2.04%)
DOW   34,299.99 (-1.63%)
QQQ   359.53 (-2.92%)
AAPL   141.83 (-2.44%)
MSFT   283.30 (-3.70%)
FB   340.45 (-3.71%)
GOOGL   2,718.74 (-3.64%)
TSLA   775.75 (-1.97%)
AMZN   3,316.98 (-2.61%)
NVDA   206.13 (-4.83%)
BABA   152.44 (+1.50%)
NIO   35.05 (-4.68%)
CGC   14.23 (-3.26%)
GE   105.72 (+0.35%)
MU   70.57 (-6.13%)
AMD   101.02 (-6.60%)
T   27.23 (-0.62%)
F   14.32 (+1.13%)
ACB   6.81 (+6.57%)
DIS   174.45 (-2.14%)
PFE   43.05 (-1.19%)
BA   218.64 (-2.46%)
AMC   36.82 (-6.31%)
S&P 500   4,352.63 (-2.04%)
DOW   34,299.99 (-1.63%)
QQQ   359.53 (-2.92%)
AAPL   141.83 (-2.44%)
MSFT   283.30 (-3.70%)
FB   340.45 (-3.71%)
GOOGL   2,718.74 (-3.64%)
TSLA   775.75 (-1.97%)
AMZN   3,316.98 (-2.61%)
NVDA   206.13 (-4.83%)
BABA   152.44 (+1.50%)
NIO   35.05 (-4.68%)
CGC   14.23 (-3.26%)
GE   105.72 (+0.35%)
MU   70.57 (-6.13%)
AMD   101.02 (-6.60%)
T   27.23 (-0.62%)
F   14.32 (+1.13%)
ACB   6.81 (+6.57%)
DIS   174.45 (-2.14%)
PFE   43.05 (-1.19%)
BA   218.64 (-2.46%)
AMC   36.82 (-6.31%)
NASDAQ:INFI

Infinity Pharmaceuticals Stock Forecast, Price & News

$3.47
-0.18 (-4.93 %)
(As of 09/28/2021 03:59 PM ET)
Add
Compare
Today's Range
$3.46
$3.62
50-Day Range
$1.52
$3.82
52-Week Range
$1.04
$5.98
Volume80,034 shs
Average Volume4.39 million shs
Market Capitalization$307.86 million
P/E RatioN/A
Dividend YieldN/A
Beta2.19
30 days | 90 days | 365 days | Advanced Chart
Receive INFI News and Ratings via Email

Sign-up to receive the latest news and ratings for Infinity Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Infinity Pharmaceuticals logo

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. It focuses on drug development. The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:INFI
CUSIP
45665G30
Employees
23
Year Founded
2000

Sales & Book Value

Annual Sales
$1.72 million
Book Value
($0.36) per share

Profitability

Net Income
$-40,490,000.00
Net Margins
-2,251.75%

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$307.86 million
Next Earnings Date
11/8/2021 (Estimated)
Optionable
Optionable

Social Links


MarketRank

Overall MarketRank

1.64 out of 5 stars

Medical Sector

949th out of 1,353 stocks

Pharmaceutical Preparations Industry

467th out of 666 stocks

Analyst Opinion: 3.5Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -












Infinity Pharmaceuticals (NASDAQ:INFI) Frequently Asked Questions

Is Infinity Pharmaceuticals a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Infinity Pharmaceuticals stock.
View analyst ratings for Infinity Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Infinity Pharmaceuticals?

Wall Street analysts have given Infinity Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Infinity Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Infinity Pharmaceuticals?

Infinity Pharmaceuticals saw a drop in short interest during the month of August. As of August 13th, there was short interest totaling 5,450,000 shares, a drop of 40.3% from the July 29th total of 9,130,000 shares. Based on an average trading volume of 7,180,000 shares, the short-interest ratio is currently 0.8 days. Currently, 6.3% of the shares of the company are short sold.
View Infinity Pharmaceuticals' Short Interest
.

When is Infinity Pharmaceuticals' next earnings date?

Infinity Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Infinity Pharmaceuticals
.

How were Infinity Pharmaceuticals' earnings last quarter?

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) posted its earnings results on Tuesday, July, 27th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.14) by $0.01. The biotechnology company had revenue of $0.51 million for the quarter, compared to analyst estimates of $0.39 million. Infinity Pharmaceuticals had a negative net margin of 2,251.75% and a negative trailing twelve-month return on equity of 304.81%.
View Infinity Pharmaceuticals' earnings history
.

How has Infinity Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Infinity Pharmaceuticals' stock was trading at $1.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, INFI shares have increased by 248.5% and is now trading at $3.52.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for INFI?

8 analysts have issued 1-year target prices for Infinity Pharmaceuticals' stock. Their forecasts range from $4.00 to $14.00. On average, they expect Infinity Pharmaceuticals' stock price to reach $9.63 in the next twelve months. This suggests a possible upside of 173.4% from the stock's current price.
View analysts' price targets for Infinity Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Infinity Pharmaceuticals' key executives?

Infinity Pharmaceuticals' management team includes the following people:
  • Adelene Q. Perkins, Chairman & Chief Executive Officer
  • Lawrence E. Bloch, President & Treasurer
  • Melissa Hackel, Vice President-Finance
  • Robert Ilaria, Chief Medical Officer
  • Seth A. Tasker, Secretary, Chief Business Officer & Senior VP

What is Adelene Q. Perkins' approval rating as Infinity Pharmaceuticals' CEO?

10 employees have rated Infinity Pharmaceuticals CEO Adelene Q. Perkins on Glassdoor.com. Adelene Q. Perkins has an approval rating of 100% among Infinity Pharmaceuticals' employees. This puts Adelene Q. Perkins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Infinity Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), OPKO Health (OPK), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Novavax (NVAX) and Celldex Therapeutics (CLDX).

What is Infinity Pharmaceuticals' stock symbol?

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

Who are Infinity Pharmaceuticals' major shareholders?

Infinity Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.81%), Vanguard Group Inc. (4.94%), Millennium Management LLC (3.44%), Geode Capital Management LLC (1.59%), State Street Corp (1.57%) and Northern Trust Corp (1.11%).
View institutional ownership trends for Infinity Pharmaceuticals
.

Which major investors are selling Infinity Pharmaceuticals stock?

INFI stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Marshall Wace LLP, Renaissance Technologies LLC, Millennium Management LLC, Cubist Systematic Strategies LLC, Susquehanna International Group LLP, Jump Financial LLC, and Goldman Sachs Group Inc..
View insider buying and selling activity for Infinity Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Infinity Pharmaceuticals stock?

INFI stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Vanguard Group Inc., Northern Trust Corp, Geode Capital Management LLC, Nuveen Asset Management LLC, GSA Capital Partners LLP, and Charles Schwab Investment Management Inc..
View insider buying and selling activity for Infinity Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Infinity Pharmaceuticals?

Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Infinity Pharmaceuticals' stock price today?

One share of INFI stock can currently be purchased for approximately $3.52.

How much money does Infinity Pharmaceuticals make?

Infinity Pharmaceuticals has a market capitalization of $312.29 million and generates $1.72 million in revenue each year. The biotechnology company earns $-40,490,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

How many employees does Infinity Pharmaceuticals have?

Infinity Pharmaceuticals employs 23 workers across the globe.

When was Infinity Pharmaceuticals founded?

Infinity Pharmaceuticals was founded in 2000.

What is Infinity Pharmaceuticals' official website?

The official website for Infinity Pharmaceuticals is www.infi.com.

Where are Infinity Pharmaceuticals' headquarters?

Infinity Pharmaceuticals is headquartered at 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138.

How can I contact Infinity Pharmaceuticals?

Infinity Pharmaceuticals' mailing address is 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138. The biotechnology company can be reached via phone at (617) 453-1000 or via email at [email protected].


This page was last updated on 9/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.